PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05057481` - Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus	Phase 3
Recruiting	`NCT05937828` - OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia
Recruiting	`NCT05263817` - A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis	Early Phase 1
Completed	`NCT03269292` - Clinical Characteristics and Treatment Outcomes of Patients With Autoimmune Hemolytic Anemia
Recruiting	`NCT05694312` - Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL	Phase 2
Completed	`NCT03538041` - A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia	Phase 2
Recruiting	`NCT03918265` - Tacrolimus Treatment for Refractory Autoimmune Cytopenia	Phase 4
Completed	`NCT02389231` - Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment	Phase 1/Phase 2
Active, not recruiting	`NCT03576742` - Severe Immune Cytopenia Registry Www.Sic-reg.Org
Active, not recruiting	`NCT04657094` - Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia	Phase 2
Recruiting	`NCT02828670` - Role of T Follicular Helper Cells in Autoimmune Hemolytic Anemia (TFH in AIHA)
Recruiting	`NCT02877706` - French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
Recruiting	`NCT05931718` - Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
Completed	`NCT02158195` - Immunopathology of Autoimmune Hemolytic Anemia
Completed	`NCT00001630` - Treatment of Autoimmune Thrombocytopenia (AITP)	Phase 1
Withdrawn	`NCT04039477` - A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP	Phase 2
Recruiting	`NCT04024202` - Data Registry of Auto Immune Hemolytic Anemia
Not yet recruiting	`NCT05711264` - Presence of Circulating Cluster of Differentiation 4 Positive 28 Null T Helper Lymphocytes(CD4+CD28-) in Patients With Autoimmune Hemolytic Anemia.
Completed	`NCT02689986` - Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease	Phase 2
Recruiting	`NCT06212154` - CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy	Phase 1

NCT number	NCT05676697
Study type	Interventional
Source	Institute of Hematology & Blood Diseases Hospital, China
Contact
Status	Terminated
Phase	Phase 1
Start date	January 13, 2023
Completion date	February 6, 2024

PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms